Our service, a fully integrated sexual health service, took part in the combined hormonal contraception (CHC) benchmarking audit, whose final report was published on 9 March 2020.1 Participation provided some positive affirmation for areas in which our service was doing well but also highlighted how poor we, and others, are at taking the opportunity to discuss long-acting reversible contraception (LARC) and explain the fundamental ‘pros and cons’ of CHC to clients. I was particularly distressed by one comment I read in the final report which said: “ We do not think that for every single CHC check patients should be informed of the risks. Those who have come to us for years understand the score well and we feel they would be ‘put off’ the service if we lectured them at every pill check”. I believe this statement demonstrates a lack of understanding about …

中文翻译：

---

对 FSRH 联合激素避孕服务提供的国家审计的评论：我们的服务学到的东西和其他人可能的学习点

我们的服务是一项全面整合的性健康服务，参与了联合激素避孕 (CHC) 基准审核，其最终报告于 2020 年 3 月 9 日发布。可怜的我们和其他人正在借此机会讨论长效可逆避孕 (LARC) 并向客户解释 CHC 的基本“利弊”。我在最终报告中读到的一条评论让我特别苦恼：“我们不认为每一次 CHC 检查都应该告知患者风险。多年来来找我们的人都非常了解分数，我们觉得如果我们在每次药片检查时向他们讲授，他们就会‘推迟’这项服务。”